产品介绍：
产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
The first potent and selective 5-HT6 antagonist. Training in cognitive tasks, as well as administration SB-271046, induces an increase in pERK1/2 and pCREB1 levels, while CREB2 levels are significantly reduced; cognition-enhancing properties of SB-271046 are attributed to the effect on pERK1/2, not pCREB1/2. SB-271046 reverses MK-801-induced, but not scopolamine-induced, learning impairments. However, with coadministration of galanthamine, both types of learning impairments were ameliorated.
特点和优势
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
| 经验(实验)分子式 | C20H22ClN3O3S2 · HCl |
| 分子量 | 488.45 |
| MDL编号 | MFCD10565914 |
| PubChem化学物质编号 | 329824453 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 溶解性 | DMSO: >20 mg/mL |
| 创始人 | GlaxoSmithKline |
| 储存温度 | 2-8℃ |
| SMILES string | Cl.COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N4CCNCC4 |
| InChI | 1S/C20H22ClN3O3S2.ClH/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24;/h3-6,11-12,22-23H,7-10H2,1-2H3;1H |
| InChI key | RMXZRJYGJMSDQK-UHFFFAOYSA-N |
安全信息
| 储存分类代码 | 11 - Combustible Solids |
| WGK | nwg |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
